You searched for Obinutuzumab - Page 4 of 17

ASH 2021: Dr. Nitin Jain on First-Line Triple Combination Therapy with Venetoclax, Obinutuzumab, and Atezolizumab for Chronic Lymphocytic Leukemia (CLL)

June 21, 2022

At the American Society of Hematology (ASH) 2021, Dr. Nicole Lamanna, Associate Clinical Professor of Medicine at Columbia University Medical Center, interviewed Dr. Nitin Jain, Associate Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center. They discussed early results from an ongoing study of a triple combination therapy with venetoclax, obinutuzumab, and atezolizumab, a PD-L1 checkpoint inhibitor.

ASH 2021: Dr. Alexey Danilov on SYK Inhibitor Entospletinib in Combination with Obinutuzumab for Chronic Lymphocytic Leukemia (CLL)

June 14, 2022

Chairman of the Board and President, interviewed Dr. Alexey Danilov, Associate Director of the Toni Stephenson Lymphoma Center at City of Hope in Duarte, CA. They discussed the final results of a phase 1/2 clinical trial of entospletinib combined with obinutuzumab in patients with relapsed/refractory CLL.

ASH 2021: Dr. Jennifer Woyach on a Clinical Trial in Progress with Combination Ibrutinib, Venetoclax, and Obinutuzumab

June 2, 2022

Discussion of a phase 3 clinical trial in progress, investigating the efficacy of the triple combination of ibrutinib plus venetoclax and obinutuzumab with response-dependent discontinuation.

A CLL Trial in Progress for Those Who Relapsed After Venetoclax Plus Obinutuzumab

March 16, 2022

Here we review ReVenG, a phase 2 study of venetoclax plus obinutuzumab retreatment (“second time”) in patients with relapsed chronic lymphocytic leukemia (CLL) (ClinicalTrials.gov Identifier: NCT04895436) that fits that category. It was presented at ASH 2021 by Dr. Matthew Davids.

ASH 2021: Matching-Adjusted Indirect Treatment Comparison (MAIC) of Acalabrutinib Alone or in Combination with Obinutuzumab Versus Ibrutinib or Venetoclax Plus Obinutuzumab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia

March 16, 2022

Acalabrutinib (A) and ibrutinib (I) are both highly effective Bruton tyrosine kinase (BTK) inhibitors approved for the treatment of chronic lymphocytic leukemia (CLL) and given as continuous treatments until disease progression or unacceptable toxicity.

Does acalabrutinib work in the birc3 mutation? Or is venetoclax obinutuzumab better?

January 17, 2022

Ask the Doctor Question: I have to start my first therapy soon and living in Germany. First diagnosis in 2015 and until now, watch and wait. ighv mutated, trisomie12, birc3 mutation.

ASH 2020: Dr. Davids Discusses Phase II AVO Study of Acalabrutinib + Venetoclax + Obinutuzumab for Chronic Lymphocytic Leukemia (CLL)

November 24, 2021

This video was recorded at the 62nd Annual Meeting of the American Society of Hematology, held virtually in December 2020. Dr. Davids specializes in CLL and serves on the CLL Society’s Medical Advisory Board.

ASCO 2021 Top Pick #12: Acalabrutinib ± Obinutuzumab Versus Obinutuzumab + Chlorambucil in Treatment-Naïve Chronic Lymphocytic Leukemia: ELEVATE-TN Four-Year Follow Up

October 4, 2021

While hardly groundbreaking, the four-year follow-up data of the ELEVATE-TN trial affirms our confidence that acalabrutinib is a strong choice for frontline therapy in CLL.

EHA 2021 Top Pick #11: Fixed-Duration Ibrutinib and Venetoclax (I+V) Versus Chlorambucil Plus Obinutuzumab (Clb+O) for First Line (1L) Chronic Lymphocytic Leukemia (CLL): Primary Analysis of the Phase 3 GLOW Study